Clinical Trials

Beaumont Health System, with three hospitals in the northern Detroit suburbs serving southern Michigan and beyond, is a highly productive contributor to clinical trials across the nation. The Beaumont Research Institute, established by the hospital’s Board of Trustees in 1966, strengthens Beaumont's ability to conduct medical research and to provide a research training experience for the medical staff and participants in graduate medical education programs.

[PROTOCOL 25-3002] PIVOTAL CLINICAL STUDY OF THE CARDIOFOCUS ENDOSCOPIC ABLATION SYSTEM - ADAPTIVE CONTACT (EAS-AC) OR HEARTLIGHT FOR THE TREATMENT OF SYMPTOMATIC ATRIAL FIBRILLATION

Status: open and enrolling

Approval Date: 2/14/2012

The purpose of this study is to demonstrate the safety and effectiveness of the CardioFocus Endoscopic Ablation System with Adaptive Contact (HeartLight) in the treatment of atrial fibrillation by creating electrical isolation of the pulmonary veins.


EVALUATION OF AN ORAL NUTRITIONAL SUPPLEMENT CONTAINING AN777 IN OLDER HOSPITALIZED PATIENTS (PROTOCOL NUMBER BK33)

Status: closed

Approval Date: 2/1/2012

To evaluate the effect of an experimental oral nutritional supplement containing AN777 compared to another oral nutritional supplement in a malnourished, elderly population.


A PHASE 2a MULTICENTER, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY EVALUATING SAFETY, TOLERABILITY AND EFFICACY OF LIRIS® IN WOMEN WITH INTERSTITIAL CYSTITIS FOLLOWED BY AN OPEN LABEL EXTENSION (Protocol TAR-100-201)

Status: open and enrolling

Approval Date: 1/27/2012

The purpose of this study is to determine if LiRIS®, an investigational drug-delivery system, is safe, tolerable and effective in women with Interstitial Cystitis. LiRIS® is inserted into the bladder via cystoscopy , remains in the bladder for 14 days, and is removed via cystoscopy.


A PHASE III INTERNATIONAL, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF 300 MG OR 600 MG OF INTRAVENOUS ZANAMIVIR TWICE DAILY COMPARED TO 75 MG OF ORAL OSELTAMIVIR TWICE DAILY IN THE TREATMENT OF HOSPITALIZED ADULTS

A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza. (ZORO)

Status: open and enrolling

Approval Date: 1/23/2012

The purpose of this study is to test the safety and efficacy of zanamivir given intravenously and how well it works at two different doses in hospitalized adolescents and adults with flu. Zanamivir will be compared with oseltamivir, which is used for treating flu.


[Protocol TG-MV-014] A RANDOMIZED, SHAM-CONTROLLED, DOUBLE-MASKED, MULTICENTER TRIAL EVALUATING OCRIPLASMIN TREATMENT FOR SYMPTOMATIC VITREOMACULAR ADHESION INCLUDING MACULAR HOLE (OASIS)

Status: open and enrolling

Approval Date: 1/6/2012

The purpose of this study is to evaluate the treatment of symptomatic vitreomacular adhesion including macular hole with ocriplasmin.